Skip to main content

Videos

Efstathios Kastritis, MD
Videos
01/15/2025
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the...
01/15/2025
Oncology
Christina Poh, MD
Videos
01/15/2025
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitimab to...
01/15/2025
Oncology
Charles Geyer, MD
Conference Coverage
01/14/2025
Charles Geyer, MD, discusses results from the phase 3 NSABP B-59/GBG-96-GeparDouze trial which assessed the efficacy of neoadjuvant atezolizumab and chemotherapy plus adjuvant atezolizumab in a cohort of patients with stage 2/3...
Charles Geyer, MD, discusses results from the phase 3 NSABP B-59/GBG-96-GeparDouze trial which assessed the efficacy of neoadjuvant atezolizumab and chemotherapy plus adjuvant atezolizumab in a cohort of patients with stage 2/3...
Charles Geyer, MD, discusses...
01/14/2025
Oncology
Paolo Tarantino, MD, PhD
Conference Coverage
01/13/2025
Paolo Tarantino, MD, PhD, discusses results from a real-world analysis which evaluated the the eligibility of a real-world population of patients with early breast cancer for adjuvant CDK4/6 inhibitors and the risk of recurrence.
Paolo Tarantino, MD, PhD, discusses results from a real-world analysis which evaluated the the eligibility of a real-world population of patients with early breast cancer for adjuvant CDK4/6 inhibitors and the risk of recurrence.
Paolo Tarantino, MD, PhD,...
01/13/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
Alexis LeVee, MD
Conference Coverage
01/13/2025
Alexis LeVee, MD, discusses results from a multi-institutional study which identified the incidence and risk factors associated with immune-related adverse events in a cohort of patients with early breast cancer treated with immune checkpoint...
Alexis LeVee, MD, discusses results from a multi-institutional study which identified the incidence and risk factors associated with immune-related adverse events in a cohort of patients with early breast cancer treated with immune checkpoint...
Alexis LeVee, MD, discusses...
01/13/2025
Oncology
Gilles Salles, MD, PhD
Videos
01/07/2025
According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant (PFS benefit vs R-CHOP among patients with intermediate-...
According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant (PFS benefit vs R-CHOP among patients with intermediate-...
According to a prolonged...
01/07/2025
Oncology
Hang Quach, MD, FRACP, FRCPA, MBBS
Videos
01/06/2025
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose...
01/06/2025
Oncology
Adam Olszewski, MD
Videos
01/06/2025
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus...
01/06/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology